Roth Capital Upgrades Peregrine Pharmaceuticals (PPHM) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St set for lower open as bond yields climb; Walmart falls
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Peregrine Pharmaceuticals (PPHM) Said Internal Review Show Discrepancies Isolated to Placebo
January 7, 2013 8:40 AM ESTPeregrine Pharmaceuticals, Inc.(NASDAQ: PPHM) provided an update from its internal review of discrepancies from its Phase II randomized, double-blind placebo-controlled trial of bavituximab in second-line non-small cell lung cancer (NSCLC) in 121 patients.
The review was prompted by the discovery of vial coding discrepancies while preparing for an end of Phase II meeting with the FDA. The... More
